Sun Pharmaceutical had sought grant of 'emergency authorisation status' to its plant-based drug, ACQH, which is being developed as a potential treatment for dengue.
Sun Pharma said human safety study of AQCH already completed, clinical trials will be conducted across 12 centres on 210 patients. The treatment duration will be 10 days.
The Mumbai-based drug-maker has submitted a proposal to the govt to conduct Phase II clinical trials of the drug to see if it can treat patients suffering from Covid-19.
The latest probe points to challenges for India’s biggest drugmaker after whistle-blower complaints on corporate governance lapses triggered a stock slide last year.
In 2015, billionaire Dilip Shanghvi bought 23% stake for Rs 18 billion, but Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.
French newspaper La Tribune earlier last week indicated that UAE withdrew from deal to fund EUR 3.5 billion. India is looking to order 114 new Rafales, which could include the F5.
China patiently invested capital, skill and technology in coal gasification. Unlike it, we won’t move from words to action. As crude prices decline, we lose interest.
COMMENTS